Helena A. Yu

And, but there's higher toxicity.

And so there's been a lot of work, including there was an ASCO presentation this year that was presented as well as work by Helena Yu to try to figure out, well, who really benefits from quote unquote escalating therapy? And from the clinical trial, phase three clinical trials that showed these combinations were better, the patients that cleared their ctDNA did well regardless whether they got more therapy or less therapy.

So if you cleared your therapy with just the pill, you did pretty much quite as well.

So a lot of us in those cases are using that to say, should we escalate therapy? Or I had a patient who had all these high-risk features, and I said, look, You have an ocular met, a brain met.